Summit Therapeutics Inc. / Fundamentals

    Income statement

    Net revenue
    €0.00
    Cost of goods sold
    €12.94M
    Gross profit
    -€49.19K
    SG&A expenses
    €354.51M
    R&D expenses
    €300.69M
    EBITDA
    -€641.42M
    D&A
    €12.95K
    EBIT
    -€655.06M
    Interest expenses
    €2.13M
    EBT
    -€643.87M
    Tax expenses
    €20.71K
    Net income
    -€643.89M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    €12.78M
    Changes in working capital
    €6.91M
    Operating cash flow
    -€178.68M
    Capex
    €426.48K
    Other investing cash flow
    -€12.58M
    Net investing cash flow
    €246.64M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €239.83M
    Debt repayment
    -€86.30M
    Other financing cash flow
    €10.82M
    Net financing cash flow
    €164.35M
    Foreign exchange effects
    €90.62K
    Net change in cash
    €232.53M
    Cash at end of period
    €257.35M
    Free cash flow
    -€178.25M

    Balance sheet

    Cash and cash equivalents
    €257.07M
    Cash and short-term investments
    €257.07M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €9.81M
    Total current assets
    €266.89M
    Property, plant & equipment
    €5.39M
    Goodwill
    €1.76M
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €5.62M
    Total non-current assets
    €12.77M
    Total assets
    €279.66M
    Accounts payable
    €19.83M
    Short-term debt
    €2.69M
    Other current liabilities
    €29.54M
    Total current liabilities
    €52.06M
    Long-term debt
    €2.10M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €1.59M
    Total non-current liabilities
    €3.69M
    Total liabilities
    €55.75M
    Common stock
    €6.41M
    Retained earnings
    -€1.59B
    Other equity
    -€2.38M
    Total equity
    €223.91M
    Total liabilities and shareholders' equity
    €279.66M

    Company information

    Market capitalization
    €13.05B
    Employees
    159
    Enterprise Value
    €14.24B

    Company ratios

    Gross margin
    0.0%
    EBITDA margin
    0.0%
    EBIT margin
    0.0%
    EBT margin
    0.0%
    Net margin
    0.0%
    ROE
    -287.6% Much better than peer group: -1,076.4%
    ROA
    -230.2% Much better than peer group: -875.7%
    Asset turnover
    0.0%
    FCF margin
    0.0%
    FCF yield
    -1.4%
    Efficiency ratio
    0.0%
    Net sales per employee
    €0.00
    Net income per employee
    -€4.05M

    Notifications